Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation
Reconstitution of human cytomegalovirus (HCMV)–specific cytotoxic T lymphocytes (CTLs), predominantly directed against pp65, provides protective immunity for the development of HCMV disease after allogeneic stem cell transplantation (SCT). To define pp65-derived CTL epitopes that would allow sensiti...
Gespeichert in:
Veröffentlicht in: | Blood 2002-05, Vol.99 (10), p.3830-3837 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3837 |
---|---|
container_issue | 10 |
container_start_page | 3830 |
container_title | Blood |
container_volume | 99 |
creator | Hebart, Holger Daginik, Senay Stevanovic, Stefan Grigoleit, Ulrich Dobler, Andrea Baur, Manuela Rauser, Georg Sinzger, Christian Jahn, Gerhard Loeffler, Juergen Kanz, Lothar Rammensee, Hans-Georg Einsele, Hermann |
description | Reconstitution of human cytomegalovirus (HCMV)–specific cytotoxic T lymphocytes (CTLs), predominantly directed against pp65, provides protective immunity for the development of HCMV disease after allogeneic stem cell transplantation (SCT). To define pp65-derived CTL epitopes that would allow sensitive detection of HCMV-specific immune reconstitution, a computer-based epitope prediction was performed. Peptide-specific CTL responses were assessed by interferon-γ release. With this approach, pp65-derived epitopes presented by the HLA alleles A*0101, A*0201, A*1101, and B*0702 were identified. The frequency of CTLs in healthy HCMV-seropositive individuals ranged from about 0.1% to 3.3% of all CD8+ T cells. In patients at risk of HCMV infection after allogeneic SCT, HCMV-peptide–specific CTLs were found in 14 of 19 patients at a median of 90 days after SCT (range, 35-234 days) and HCMV-antigen–specific CD4+ T lymphocytes in 11 of 18 patients at a median of 90 days after SCT (range, 35->180 days). Peak counts of peptide-specific CD8+ T cells ranged from 0.14 to 60.6 cells/μL; those of protein-specific CD4+ T cells ranged from 0.64 to 18.97 cells/μL. Reconstitution of HCMV-peptide–specific CD8+ T cells and protein-specific CD4+ T cells was associated with clearance of HCMV infection (r2 = 0.89, P < .0001 and r2 = 0.61, P = .0045, respectively). HCMV infection recurred after documentation of HCMV-specific T-cell reconstitution (n = 4) when immunosuppression was intensified. Patients in whom late-onset HCMV disease developed lacked HCMV-protein–specific T cells at 3 months after SCT. In conclusion, prospective monitoring of HCMV-specific CD4+ and CD8+ T-cell reconstitution can be performed rapidly by using flow cytometry after specific stimulation with HCMV peptides and proteins and might help to further improve clinical management of HCMV infection after allogeneic SCT. |
doi_str_mv | 10.1182/blood.V99.10.3830 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71645969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120608679</els_id><sourcerecordid>71645969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-447b9d0c5ae83fe53e3dc948fb096e705d091f2e35038dd1ba5889bd275510413</originalsourceid><addsrcrecordid>eNp9ks-O1SAUxhujca6jD-DGsNFdr1BKW-LKTPyXTOLC0W1D4TAXpVCB3rGufAcfxffwIXwJt9J7bzI7V8Dhd75zOB9F8ZjgLSFd9Xyw3qvtJ863OUI7iu8UG8KqrsS4wneLDca4KWvekrPiQYyfMSY1rdj94owQ3jVVTTfF3w_goklmD0hBApmMd8hrtJtH4ZBckh_hWli_N2GOaIIpGQV_fvyME0ijjTwgyX_Lu6vSLuO08zkCKECcvIsQ0bAg4xIEDcG78vevnAzu-zJCaY37AgqZcZydz3hCIkaxIOEU0tbfnMqnsCqgHQibdutWmb1Rs7DxQOarSSQDLuWzzoWQsNZfg4PcU0wwIgnWohSEi5MVLon1jQ-LezorwKPTel58fP3q6uJtefn-zbuLl5elrFucyrpuB66wZAI6qoFRoEryutMD5g20mCnMia6AMkw7pcggWNfxQVUtYwTXhJ4Xz466U_BfZ4ipH01cGxIO_Bz7ljQ14w3PIDmCMvgYA-h-CmYUYekJ7le3-4PbfXZ7jaxu55wnJ_F5GEHdZpzszcDTEyCiFFbnGUgTbznaNIR1beZeHDnIo9gbCH2UeaISlAn5T_TKm_-08Q_3VdTH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71645969</pqid></control><display><type>article</type><title>Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hebart, Holger ; Daginik, Senay ; Stevanovic, Stefan ; Grigoleit, Ulrich ; Dobler, Andrea ; Baur, Manuela ; Rauser, Georg ; Sinzger, Christian ; Jahn, Gerhard ; Loeffler, Juergen ; Kanz, Lothar ; Rammensee, Hans-Georg ; Einsele, Hermann</creator><creatorcontrib>Hebart, Holger ; Daginik, Senay ; Stevanovic, Stefan ; Grigoleit, Ulrich ; Dobler, Andrea ; Baur, Manuela ; Rauser, Georg ; Sinzger, Christian ; Jahn, Gerhard ; Loeffler, Juergen ; Kanz, Lothar ; Rammensee, Hans-Georg ; Einsele, Hermann</creatorcontrib><description>Reconstitution of human cytomegalovirus (HCMV)–specific cytotoxic T lymphocytes (CTLs), predominantly directed against pp65, provides protective immunity for the development of HCMV disease after allogeneic stem cell transplantation (SCT). To define pp65-derived CTL epitopes that would allow sensitive detection of HCMV-specific immune reconstitution, a computer-based epitope prediction was performed. Peptide-specific CTL responses were assessed by interferon-γ release. With this approach, pp65-derived epitopes presented by the HLA alleles A*0101, A*0201, A*1101, and B*0702 were identified. The frequency of CTLs in healthy HCMV-seropositive individuals ranged from about 0.1% to 3.3% of all CD8+ T cells. In patients at risk of HCMV infection after allogeneic SCT, HCMV-peptide–specific CTLs were found in 14 of 19 patients at a median of 90 days after SCT (range, 35-234 days) and HCMV-antigen–specific CD4+ T lymphocytes in 11 of 18 patients at a median of 90 days after SCT (range, 35->180 days). Peak counts of peptide-specific CD8+ T cells ranged from 0.14 to 60.6 cells/μL; those of protein-specific CD4+ T cells ranged from 0.64 to 18.97 cells/μL. Reconstitution of HCMV-peptide–specific CD8+ T cells and protein-specific CD4+ T cells was associated with clearance of HCMV infection (r2 = 0.89, P < .0001 and r2 = 0.61, P = .0045, respectively). HCMV infection recurred after documentation of HCMV-specific T-cell reconstitution (n = 4) when immunosuppression was intensified. Patients in whom late-onset HCMV disease developed lacked HCMV-protein–specific T cells at 3 months after SCT. In conclusion, prospective monitoring of HCMV-specific CD4+ and CD8+ T-cell reconstitution can be performed rapidly by using flow cytometry after specific stimulation with HCMV peptides and proteins and might help to further improve clinical management of HCMV infection after allogeneic SCT.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V99.10.3830</identifier><identifier>PMID: 11986243</identifier><language>eng</language><publisher>Washington, DC: Elsevier Inc</publisher><subject>Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Viral - blood ; Antigens, Viral - immunology ; Biological and medical sciences ; Blood Donors ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cell Line ; Cells, Cultured ; Cytomegalovirus - immunology ; Cytomegalovirus Infections - immunology ; Cytomegalovirus Infections - prevention & control ; Enzyme-Linked Immunosorbent Assay - methods ; Epitopes - immunology ; Female ; Flow Cytometry - methods ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Interferon-gamma - analysis ; Kinetics ; Leukapheresis ; Male ; Mathematical Computing ; Medical sciences ; Middle Aged ; Peptides - immunology ; Phosphoproteins - immunology ; Sensitivity and Specificity ; T-Lymphocytes, Cytotoxic - immunology ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation, Homologous ; Viral Matrix Proteins - immunology</subject><ispartof>Blood, 2002-05, Vol.99 (10), p.3830-3837</ispartof><rights>2002 American Society of Hematology</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-447b9d0c5ae83fe53e3dc948fb096e705d091f2e35038dd1ba5889bd275510413</citedby><cites>FETCH-LOGICAL-c470t-447b9d0c5ae83fe53e3dc948fb096e705d091f2e35038dd1ba5889bd275510413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13661587$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11986243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hebart, Holger</creatorcontrib><creatorcontrib>Daginik, Senay</creatorcontrib><creatorcontrib>Stevanovic, Stefan</creatorcontrib><creatorcontrib>Grigoleit, Ulrich</creatorcontrib><creatorcontrib>Dobler, Andrea</creatorcontrib><creatorcontrib>Baur, Manuela</creatorcontrib><creatorcontrib>Rauser, Georg</creatorcontrib><creatorcontrib>Sinzger, Christian</creatorcontrib><creatorcontrib>Jahn, Gerhard</creatorcontrib><creatorcontrib>Loeffler, Juergen</creatorcontrib><creatorcontrib>Kanz, Lothar</creatorcontrib><creatorcontrib>Rammensee, Hans-Georg</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><title>Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation</title><title>Blood</title><addtitle>Blood</addtitle><description>Reconstitution of human cytomegalovirus (HCMV)–specific cytotoxic T lymphocytes (CTLs), predominantly directed against pp65, provides protective immunity for the development of HCMV disease after allogeneic stem cell transplantation (SCT). To define pp65-derived CTL epitopes that would allow sensitive detection of HCMV-specific immune reconstitution, a computer-based epitope prediction was performed. Peptide-specific CTL responses were assessed by interferon-γ release. With this approach, pp65-derived epitopes presented by the HLA alleles A*0101, A*0201, A*1101, and B*0702 were identified. The frequency of CTLs in healthy HCMV-seropositive individuals ranged from about 0.1% to 3.3% of all CD8+ T cells. In patients at risk of HCMV infection after allogeneic SCT, HCMV-peptide–specific CTLs were found in 14 of 19 patients at a median of 90 days after SCT (range, 35-234 days) and HCMV-antigen–specific CD4+ T lymphocytes in 11 of 18 patients at a median of 90 days after SCT (range, 35->180 days). Peak counts of peptide-specific CD8+ T cells ranged from 0.14 to 60.6 cells/μL; those of protein-specific CD4+ T cells ranged from 0.64 to 18.97 cells/μL. Reconstitution of HCMV-peptide–specific CD8+ T cells and protein-specific CD4+ T cells was associated with clearance of HCMV infection (r2 = 0.89, P < .0001 and r2 = 0.61, P = .0045, respectively). HCMV infection recurred after documentation of HCMV-specific T-cell reconstitution (n = 4) when immunosuppression was intensified. Patients in whom late-onset HCMV disease developed lacked HCMV-protein–specific T cells at 3 months after SCT. In conclusion, prospective monitoring of HCMV-specific CD4+ and CD8+ T-cell reconstitution can be performed rapidly by using flow cytometry after specific stimulation with HCMV peptides and proteins and might help to further improve clinical management of HCMV infection after allogeneic SCT.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens, Viral - immunology</subject><subject>Biological and medical sciences</subject><subject>Blood Donors</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cell Line</subject><subject>Cells, Cultured</subject><subject>Cytomegalovirus - immunology</subject><subject>Cytomegalovirus Infections - immunology</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>Flow Cytometry - methods</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Interferon-gamma - analysis</subject><subject>Kinetics</subject><subject>Leukapheresis</subject><subject>Male</subject><subject>Mathematical Computing</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Peptides - immunology</subject><subject>Phosphoproteins - immunology</subject><subject>Sensitivity and Specificity</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation, Homologous</subject><subject>Viral Matrix Proteins - immunology</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks-O1SAUxhujca6jD-DGsNFdr1BKW-LKTPyXTOLC0W1D4TAXpVCB3rGufAcfxffwIXwJt9J7bzI7V8Dhd75zOB9F8ZjgLSFd9Xyw3qvtJ863OUI7iu8UG8KqrsS4wneLDca4KWvekrPiQYyfMSY1rdj94owQ3jVVTTfF3w_goklmD0hBApmMd8hrtJtH4ZBckh_hWli_N2GOaIIpGQV_fvyME0ijjTwgyX_Lu6vSLuO08zkCKECcvIsQ0bAg4xIEDcG78vevnAzu-zJCaY37AgqZcZydz3hCIkaxIOEU0tbfnMqnsCqgHQibdutWmb1Rs7DxQOarSSQDLuWzzoWQsNZfg4PcU0wwIgnWohSEi5MVLon1jQ-LezorwKPTel58fP3q6uJtefn-zbuLl5elrFucyrpuB66wZAI6qoFRoEryutMD5g20mCnMia6AMkw7pcggWNfxQVUtYwTXhJ4Xz466U_BfZ4ipH01cGxIO_Bz7ljQ14w3PIDmCMvgYA-h-CmYUYekJ7le3-4PbfXZ7jaxu55wnJ_F5GEHdZpzszcDTEyCiFFbnGUgTbznaNIR1beZeHDnIo9gbCH2UeaISlAn5T_TKm_-08Q_3VdTH</recordid><startdate>20020515</startdate><enddate>20020515</enddate><creator>Hebart, Holger</creator><creator>Daginik, Senay</creator><creator>Stevanovic, Stefan</creator><creator>Grigoleit, Ulrich</creator><creator>Dobler, Andrea</creator><creator>Baur, Manuela</creator><creator>Rauser, Georg</creator><creator>Sinzger, Christian</creator><creator>Jahn, Gerhard</creator><creator>Loeffler, Juergen</creator><creator>Kanz, Lothar</creator><creator>Rammensee, Hans-Georg</creator><creator>Einsele, Hermann</creator><general>Elsevier Inc</general><general>The Americain Society of Hematology</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020515</creationdate><title>Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation</title><author>Hebart, Holger ; Daginik, Senay ; Stevanovic, Stefan ; Grigoleit, Ulrich ; Dobler, Andrea ; Baur, Manuela ; Rauser, Georg ; Sinzger, Christian ; Jahn, Gerhard ; Loeffler, Juergen ; Kanz, Lothar ; Rammensee, Hans-Georg ; Einsele, Hermann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-447b9d0c5ae83fe53e3dc948fb096e705d091f2e35038dd1ba5889bd275510413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens, Viral - immunology</topic><topic>Biological and medical sciences</topic><topic>Blood Donors</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cell Line</topic><topic>Cells, Cultured</topic><topic>Cytomegalovirus - immunology</topic><topic>Cytomegalovirus Infections - immunology</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>Flow Cytometry - methods</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Interferon-gamma - analysis</topic><topic>Kinetics</topic><topic>Leukapheresis</topic><topic>Male</topic><topic>Mathematical Computing</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Peptides - immunology</topic><topic>Phosphoproteins - immunology</topic><topic>Sensitivity and Specificity</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation, Homologous</topic><topic>Viral Matrix Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hebart, Holger</creatorcontrib><creatorcontrib>Daginik, Senay</creatorcontrib><creatorcontrib>Stevanovic, Stefan</creatorcontrib><creatorcontrib>Grigoleit, Ulrich</creatorcontrib><creatorcontrib>Dobler, Andrea</creatorcontrib><creatorcontrib>Baur, Manuela</creatorcontrib><creatorcontrib>Rauser, Georg</creatorcontrib><creatorcontrib>Sinzger, Christian</creatorcontrib><creatorcontrib>Jahn, Gerhard</creatorcontrib><creatorcontrib>Loeffler, Juergen</creatorcontrib><creatorcontrib>Kanz, Lothar</creatorcontrib><creatorcontrib>Rammensee, Hans-Georg</creatorcontrib><creatorcontrib>Einsele, Hermann</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hebart, Holger</au><au>Daginik, Senay</au><au>Stevanovic, Stefan</au><au>Grigoleit, Ulrich</au><au>Dobler, Andrea</au><au>Baur, Manuela</au><au>Rauser, Georg</au><au>Sinzger, Christian</au><au>Jahn, Gerhard</au><au>Loeffler, Juergen</au><au>Kanz, Lothar</au><au>Rammensee, Hans-Georg</au><au>Einsele, Hermann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2002-05-15</date><risdate>2002</risdate><volume>99</volume><issue>10</issue><spage>3830</spage><epage>3837</epage><pages>3830-3837</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Reconstitution of human cytomegalovirus (HCMV)–specific cytotoxic T lymphocytes (CTLs), predominantly directed against pp65, provides protective immunity for the development of HCMV disease after allogeneic stem cell transplantation (SCT). To define pp65-derived CTL epitopes that would allow sensitive detection of HCMV-specific immune reconstitution, a computer-based epitope prediction was performed. Peptide-specific CTL responses were assessed by interferon-γ release. With this approach, pp65-derived epitopes presented by the HLA alleles A*0101, A*0201, A*1101, and B*0702 were identified. The frequency of CTLs in healthy HCMV-seropositive individuals ranged from about 0.1% to 3.3% of all CD8+ T cells. In patients at risk of HCMV infection after allogeneic SCT, HCMV-peptide–specific CTLs were found in 14 of 19 patients at a median of 90 days after SCT (range, 35-234 days) and HCMV-antigen–specific CD4+ T lymphocytes in 11 of 18 patients at a median of 90 days after SCT (range, 35->180 days). Peak counts of peptide-specific CD8+ T cells ranged from 0.14 to 60.6 cells/μL; those of protein-specific CD4+ T cells ranged from 0.64 to 18.97 cells/μL. Reconstitution of HCMV-peptide–specific CD8+ T cells and protein-specific CD4+ T cells was associated with clearance of HCMV infection (r2 = 0.89, P < .0001 and r2 = 0.61, P = .0045, respectively). HCMV infection recurred after documentation of HCMV-specific T-cell reconstitution (n = 4) when immunosuppression was intensified. Patients in whom late-onset HCMV disease developed lacked HCMV-protein–specific T cells at 3 months after SCT. In conclusion, prospective monitoring of HCMV-specific CD4+ and CD8+ T-cell reconstitution can be performed rapidly by using flow cytometry after specific stimulation with HCMV peptides and proteins and might help to further improve clinical management of HCMV infection after allogeneic SCT.</abstract><cop>Washington, DC</cop><pub>Elsevier Inc</pub><pmid>11986243</pmid><doi>10.1182/blood.V99.10.3830</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 2002-05, Vol.99 (10), p.3830-3837 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_71645969 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Viral - blood Antigens, Viral - immunology Biological and medical sciences Blood Donors Bone marrow, stem cells transplantation. Graft versus host reaction Cell Line Cells, Cultured Cytomegalovirus - immunology Cytomegalovirus Infections - immunology Cytomegalovirus Infections - prevention & control Enzyme-Linked Immunosorbent Assay - methods Epitopes - immunology Female Flow Cytometry - methods Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Humans Interferon-gamma - analysis Kinetics Leukapheresis Male Mathematical Computing Medical sciences Middle Aged Peptides - immunology Phosphoproteins - immunology Sensitivity and Specificity T-Lymphocytes, Cytotoxic - immunology Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation, Homologous Viral Matrix Proteins - immunology |
title | Sensitive detection of human cytomegalovirus peptide–specific cytotoxic T-lymphocyte responses by interferon-γ–enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T07%3A00%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sensitive%20detection%20of%20human%20cytomegalovirus%20peptide%E2%80%93specific%20cytotoxic%20T-lymphocyte%20responses%20by%20interferon-%CE%B3%E2%80%93enzyme-linked%20immunospot%20assay%20and%20flow%20cytometry%20in%20healthy%20individuals%20and%20in%20patients%20after%20allogeneic%20stem%20cell%20transplantation&rft.jtitle=Blood&rft.au=Hebart,%20Holger&rft.date=2002-05-15&rft.volume=99&rft.issue=10&rft.spage=3830&rft.epage=3837&rft.pages=3830-3837&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V99.10.3830&rft_dat=%3Cproquest_cross%3E71645969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71645969&rft_id=info:pmid/11986243&rft_els_id=S0006497120608679&rfr_iscdi=true |